MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: A pilot study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
12
2018
accepted:
18
04
2019
entrez:
7
5
2019
pubmed:
7
5
2019
medline:
28
1
2020
Statut:
epublish
Résumé
Coronary artery disease (CAD) and acute myocardial infarction (AMI) are the leading causes of death worldwide. Since only a subset of CAD patients develops myocardial infarction, it is likely that unique factors predispose to AMI. Circulating microRNAs represent diagnostic powerful biomarkers for detection of heart injuries and patients' risk stratification. Using an array-based approach, the expression of 84 circulating miRNAs was analyzed in plasma of pooled stable CAD patients (CAD; n = 5) and unstable CAD patients (AMI_T0; n = 5) enrolled within 24 hours from an AMI event. The array experiments showed 27 miRNAs differentially expressed with a two-fold up- or down-regulation (10 up- and 17 down-regulated miRNAs). Among them, miR-423-5p dis-regulation was confirmed in a larger case study (n = 99). Circulating miR-423-5p resulted to be significantly down-regulated within 24 hours from the AMI event (FC = -2, p≤0.05). Interestingly, miR-423-5p expression resulted to be increased (FC = +2; p≤0.005) in a subgroup of the same AMI patients (AMI_T1; n = 11) analyzed after 6 months from the acute event. We extended miR-423-5p expression study on PBMCs (peripheral blood mononuclear cells), confirming also in this tissue its up-regulation at 6 months post-AMI. Receiver operating characteristic analyses (ROC) were performed to detect the power of miR-423-5p to discriminate stable and unstable CAD. In plasma, miR-423-5p expression accurately distinguishes stable and unstable CAD patients (AUC = 0.7143, p≤0.005). Interestingly, the highest discriminatory value (AUC = 0.8529 p≤0.0005) was identified in blood cells, where miR-423-5p expression is able to differentiate unstable CAD patients during an acute event (AMI_T0) from those at six months post-AMI (AMI_T1). Furthermore, cellular miR-423-5p may discriminate also stable CAD patients from unstable CAD patients after six months post-AMI (AUC = 0.7355 p≤0.05). The results of this pilot-study suggest that miR-423-5p expression level both in plasma and blood cells, could represent a new promising biomarker for risk stratification of CAD patients.
Identifiants
pubmed: 31059534
doi: 10.1371/journal.pone.0216363
pii: PONE-D-18-36533
pmc: PMC6502321
doi:
Substances chimiques
MIRN423 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216363Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2008 Sep 05;3(9):e3148
pubmed: 18773077
Oncotarget. 2016 Jan 19;7(3):2201-19
pubmed: 26755652
Reproduction. 2015 Jul;150(1):65-76
pubmed: 25926693
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51
pubmed: 22895665
PLoS One. 2013 Nov 15;8(11):e80345
pubmed: 24260372
Minerva Cardioangiol. 2013 Dec;61(6):627-37
pubmed: 24253456
PLoS One. 2015 Nov 12;10(11):e0142904
pubmed: 26562412
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
Nature. 2011 May 19;473(7347):317-25
pubmed: 21593864
J Am Coll Cardiol. 2014 Jun 3;63(21):2177-87
pubmed: 24583309
Curr Atheroscler Rep. 2015;17(2):476
pubmed: 25433555
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Int J Cardiol. 2018 Jan 1;250:207-214
pubmed: 28988828
Am J Transl Res. 2017 Aug 15;9(8):3796-3803
pubmed: 28861170
Clin Sci (Lond). 2010 Apr 20;119(2):87-95
pubmed: 20218970
Biomarkers. 2014 Mar;19(2):135-41
pubmed: 24506564
Circ Cardiovasc Genet. 2011 Dec;4(6):614-9
pubmed: 21956146
N Engl J Med. 2012 Jan 5;366(1):54-63
pubmed: 22216842
J Am Coll Cardiol. 2017 Aug 1;70(5):590-606
pubmed: 28750703
J Cardiovasc Med (Hagerstown). 2016 Dec;17(12):851-854
pubmed: 27467546
Circ Res. 2016 Feb 19;118(4):703-20
pubmed: 26892968
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Cardiology. 2011;118(4):217-26
pubmed: 21701171
Eur Heart J. 2010 Mar;31(6):659-66
pubmed: 20159880
Circulation. 2017 Mar 14;135(11):1005-1007
pubmed: 28289003
J Am Coll Cardiol. 2017 Apr 18;69(15):1952-1967
pubmed: 28408026
Dev Biol. 2014 Feb 1;386(1):135-51
pubmed: 24275324
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
BMC Med Genomics. 2013 May 04;6:16
pubmed: 23641832
Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17797-802
pubmed: 20876116
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Dev Cell. 2010 Apr 20;18(4):510-25
pubmed: 20412767
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
Biochem Biophys Res Commun. 2010 Jan 1;391(1):73-7
pubmed: 19896465
Eur Heart J. 2015 Dec 21;36(48):3392-403
pubmed: 26543043
Circ Res. 2010 Apr 2;106(6):1035-9
pubmed: 20185794
J Biol Chem. 2004 Jun 18;279(25):26126-33
pubmed: 15073182
Mol Med Rep. 2015 Jul;12(1):1163-8
pubmed: 25776937
Eur J Heart Fail. 2012 Feb;14(2):147-54
pubmed: 22120965
J Cardiovasc Transl Res. 2010 Jun;3(3):251-5
pubmed: 20560046
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
Proc Natl Acad Sci U S A. 2000 May 23;97(11):5735-9
pubmed: 10801981
Nucleic Acids Res. 2005 Oct 27;33(18):6024-33
pubmed: 16254079